Vaccines

Vaccine
#Vaccines

Editor’s Comment: Listening to the Science

With the news that RFK Jr – America’s Secretary of Health and Human Services – has cancelled around $500 million in funding for mRNA vaccines research, the question arises of how far political opinion can sway both medical research and society’s trust in science.  The decision by RFK Jr has… Read More

#Exclusive Content #Opinion

Close up of vaccine syringe
#Immunology / Virology & Vaccines #Mergers and acquisitions #Respiratory #Sanofi #Vaccines #Vicebio

Harnessing molecular clamp technology for respiratory vaccines

Sanofi explores the acquisition of Vicebio and its Molecular Clamp technology, highlighting how it strengthens the company’s respiratory vaccine portfolio with next-generation combination candidates. Q: Sanofi has described the acquisition of Vicebio as a step toward next-generation combination vaccines. What gaps or opportunities does this address in your existing respiratory… Read More

#Exclusive Content

Vaccine
#AI #Antibody drug conjugate (ADC) #Biopharma #Drug discovery #Vaccines

DDW Fall issue out now

The DDW Fall issue is out now and examines why there is a need for a universal pneumococcal vaccine, why China might be the next global biopharma powerhouse and looks at developments in microbiome research and the therapeutic sectors it is driving. It also features an exclusive guide exploring… Read More

#News

Vaccine
#Clinical trials #Drug discovery #Immunology / Virology & Vaccines #Vaccines

Human challenge trial for pneumococcal vaccine launches in Malawi  

The first clinical trials for a new vaccine targeting pneumococcal disease in people in Malawi have been launched.  The human challenge trial will enrol 400 people in Malawi making it the biggest trial the country has seen to date.   The launch of the trial comes… Read More

#News

Vaccine
#Clinical trials #Drug discovery #Infectious diseases #Vaccines

Research programme represents a “new frontier in vaccine science” 

The UK’s University of Oxford, through its strategic partnership with the Ellison Institute of Technology (EIT), has received research funding of £118 ($159.7) million to launch an ambitious new programme of vaccine research.  Led by the Oxford Vaccine Group, the new initiative based in the University – CoI-AI (Correlates of… Read More

#Business & Investment #News

Vaccine
#Africa #HIV #Phase I trial #Vaccines

Partners launch trial of novel HIV vaccine in Africa

A Phase I clinical trial of a novel T cell-inducing HIV vaccine candidate has launched in Africa to evaluate immune responses to highly networked HIV T-cell epitopes.  The trial is a collaboration between The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT,… Read More

#News

Monkeypox virus
#CEPI #Immunology / Virology & Vaccines #Pandemic prevention #Vaccines

Immune marker playbooks support vaccine development

CEPI and PATH are joining forces to create playbooks that map all available research into specific immune markers that indicate protection against target viruses with epidemic or pandemic potential.  Supported by $8 million in funding from CEPI, these research and development (R&D) manuals could hold important insights… Read More

#News

#Fast Track designation #FDA #mRNA #Sanofi #Vaccines

Chlamydia vaccine candidate granted fast track designation

The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need.  The chlamydia vaccine candidate… Read More

#News #Regulatory

RNA vaccine
#Drug discovery #mRNA #RNA Therapeutics #Vaccines

The evolution of the RNA therapeutics landscape 

Bruce Sullenger, PhD Founder and Scientific Advisor of Basking Biosciences, and Joseph W And Dorothy W Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University, explores the rise of RNA therapeutics.   For decades, the life sciences community held the belief… Read More

#Exclusive Content

Vaccine
#Clinical trial #Immunology / Virology & Vaccines #Interview #University of Oxford #Vaccines

Vaccines and various response rates

DDW Editor Reece Armstrong speaks to Dr Katrina Pollock from the Oxford Vaccine Group at the University of Oxford. Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the… Read More

#Exclusive Content

Vaccine
#Immunology / Virology & Vaccines #Interview #Structural biology #Vaccines

How structural biology is informing vaccine design

Reece Armstrong speaks to Melanie Adams-Cioaba, Senior Director and General Manager of pharma (cryo-EM), Thermo Fisher Scientific about advances in vaccine design. RA: How can rational design approaches help advance vaccine development?     MA: Regarding vaccine development specifically, and the role my team plays in the development of cryogenic… Read More

#Exclusive Content

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #Gene expression #Gene mutation #Interview #mRNA #Next generation sequencing #Oncology #PharmEnable #RNA sequencing #Single-cell RNA sequencing #Vaccines

Podcast: What trends will speed up the journey from clinic to bedside?

This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More

#News

Vaccine discovery
#Covid-19 #Immunity #Immunology / Virology & Vaccines #Pandemic prevention #Vaccines

Accelerating recombinant protein vaccine discovery

Listen to this article on the DDW Podcast: Vaccination responses need to be rapid, efficacious and cost-effective if they are to outpace new viral threats emerging across the globe, says Jian He (Jason), Chemistry, Manufacturing and Controls (CMC) Head, WuXi Vaccines. Technologies that hasten the pathway from vaccine discovery to… Read More

#Exclusive Content

Vaccine research
#Assays #Covid-19 #Drug efficacy #eBook #Immunology / Virology & Vaccines #Vaccines

eBook: Assessing the efficacy of vaccines through laboratory assays

The eighth eBook of the Hamilton series is now available to download for free. In ‘Assessing the Efficacy of Vaccines through Laboratory Assays‘, the authors discuss the key milestones achieved throughout the history of vaccine development, the laboratory tests commonly used to assess vaccines’ efficacy, and we… Read More

#News

#Assays #Covid-19 #Drug efficacy #Immunology / Virology & Vaccines #Vaccines

Assessing the efficacy of vaccines through laboratory assays

In the eighth eBook of the Hamilton series, ‘Assessing the Efficacy of Vaccines through Laboratory Assays’, we discuss: Vaccine development: Key milestones and impact of Covid-19 Laboratory tests commonly used to assess vaccines’ efficacy and the benefits of automating them Hamilton standardised and customised solutions for workflows such as qPCR,… Read More

#Resources

Close up of vaccine syringe
#Immunology / Virology & Vaccines #Pfizer #United States #Vaccines

US CDC recommends five-in-one meningococcal vaccine

The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend Pfizer’s Penbraya (meningococcal group A, B, C, W and Y vaccine) for the prevention of the five most common meningococcal serogroups. These serogroups cause the majority of… Read More

#News